The Future of Drug Regulation: An Interview With Center for Drug Evaluation & Research Director Janet Woodcock
This article was originally published in RPM Report
FDA’s top drug regulator sat down for us for an interview about the agency’s efforts to build a higher quality regulatory system in the US—one that focuses on the “content” of regulatory standards rather than just the process. The discussion touched on the need for new and improved standards in classes like weight loss and rheumatology (albeit for very different reasons); the characteristics that make for good drug reviewers (and their managers); and on the drug center’s responsibility for preserving private sector drug development.
You may also be interested in...
FDA Eager For More Master Protocols in Oncology: Approach Means Lower Cost For Sponsors—and Less Control
FDA officials are enthusiastic about broad, multi-agent cancer trials built on the I-SPY model. For sponsors, the trials mean less control over the development path and ultimate value proposition for the therapy—but may have important benefits on defending high prices for truly effective new therapies.
The Center for Drug Evaluation & Research is working with George Washington University as a “neutral convener” to rethink weight loss drug development standards. That may make for an unexpected legacy from the wave of failed weight loss candidates from 2010: a whole new approach to drug development guidance from FDA.
Everyone knows R&D productivity has dipped to levels that threaten the private drug development model, and almost everyone says regulatory hurdles are part of the problem. That isn’t how FDA sees it. One thing is clear: blaming FDA won’t help anyone, so it may be time to pay more attention to FDA’s ideas for solutions rather than continue to point fingers.